Amplia Therapeutics (ASX:ATX): Clinical Trials, R&D Rebate and FY26 Results

Aditi Sarkar

23 October 2026 04:27 PM AEDT

Amplia Therapeutics (ASX:ATX): Clinical Trials, R&D Rebate and FY26 Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Amplia Therapeutics (ASX:ATX) updated progress across its pancreatic and ovarian cancer trials.
ACCENT retained one participant, while two others had completed 24 months on study.
The company received an AUD 4.78 million research and development tax rebate.
FY26 cash holdings were AUD 27.85 million, with a reported loss of AUD 7.71 million.

Amplia Therapeutics Limited develops investigational focal adhesion kinase (FAK) inhibitors for cancer and fibrotic diseases, with clinical research focused on pancreatic cancer. At the time of writing on 23 October 2026, Amplia Therapeutics (ASX:ATX) was quoted at AUD 0.078, unchanged at 0.00% for the trading session. Its latest disclosures address patient progress in the ACCENT and AMPLICITY studies, planned trials in other cancer settings and receipt of an Australian research tax rebate.

Company Business

Amplia Therapeutics (ASX:ATX) is a clinical-stage pharmaceutical developer rather than a commercial supplier of approved cancer medicines. Its lead drug candidate, narmafotinib, also called AMP945, inhibits FAK, a protein implicated in tumour growth and the environment surrounding cancer cells. Clinical studies are testing whether this investigational medicine can be combined safely and effectively with established chemotherapy regimens.

The company also holds rights relating to AMP886, another FAK-targeting research compound. Research activities span pancreatic cancer and potential applications in ovarian and lung cancer, with clinical programs at Australian and international sites. Clinical development requires regulatory and ethics permissions before planned trials can proceed.

Recent Development

In an update released on 22 October 2026, Amplia Therapeutics (ASX:ATX) reported that one participant remained in its ACCENT pancreatic cancer study at 19 months, while two participants had completed 24 months. ACCENT combines narmafotinib with gemcitabine and nab-paclitaxel. The company has separately reported an objective response rate of 36% and median overall survival of 11.1 months; these findings are clinical-study outcomes, not evidence of regulatory approval.

For AMPLICITY, which combines narmafotinib with modified FOLFIRINOX chemotherapy, one confirmed and one unconfirmed partial response had been recorded. One participant remained in the trial. Recruitment had been halted after three dose-limiting toxicities attributed by the company to the chemotherapy regimen. The pause is a relevant constraint on future clinical development.

The planned ACCENT-MINI study had selected three Australian sites and submitted its ethics application. In parallel, the PRROSE ovarian cancer protocol was finalised, and ethics approval was submitted. PRROSE is planned to assess narmafotinib alongside carboplatin and paclitaxel in patients showing inadequate initial chemotherapy response. These are proposed studies, with recruitment and results dependent on subsequent approvals and implementation.

Financial Performance and Sector Context

For the financial year ended 31 March 2026, Amplia Therapeutics (ASX:ATX) reported a net loss after tax of AUD 7.71 million and research and development expenditure of AUD 9.08 million. The company raised AUD 27.65 million of capital during FY26 and held cash and cash equivalents of AUD 27.85 million at year-end. It reported no borrowings or dividends for that reporting date.

On 22 October, the company announced receipt of an AUD 4,778,235.52 research and development tax rebate for FY26. The refund relates to qualifying research on its FAK inhibitors, predominantly clinical activity involving narmafotinib. The cash receipt adds funding to support research programs, but does not represent revenue from commercial medicine sales or determine the outcome of any trial.

Drug developers face expenditure for patient enrolment, manufacturing, safety monitoring, data analysis and regulatory submissions. Timelines can change when ethics reviews, treatment-related adverse events or site requirements affect studies. For Amplia, trial spending and the timing of tax incentives and new funding remain significant financial considerations.

Risks to Consider

Amplia Therapeutics (ASX:ATX) is exposed to clinical efficacy and safety uncertainty, including the recruitment halt affecting AMPLICITY. Its candidates have not been established as approved products. Trial initiation depends on ethics clearance, participating sites and enrolment. Further spending may require external capital, potentially diluting existing shareholders. The company also faces manufacturing, intellectual-property, regulatory and study-execution risks.

What to Watch Next

Upcoming milestones for Amplia Therapeutics (ASX:ATX) include ethics decisions for ACCENT-MINI and PRROSE, site activation and any recruitment updates. The company expects ACCENT-MINI safety and pharmacokinetic information in late Q1 or early Q2 2027 for inclusion in a proposed US regulatory protocol submission. Further reports on the ACCENT biomarker analysis and the planned lung-cancer combination study will also be relevant.

Key Insights

Amplia’s October disclosures combine continuing clinical follow-up with preparations for additional studies. The AUD 4.78 million tax rebate provides cash for research activities, while FY26 results underline the costs associated with drug development. For Amplia Therapeutics (ASX:ATX), upcoming evidence will centre on regulatory permissions, patient safety, clinical data and available funding.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.